Texas Permanent School Fund Corp Has $8.36 Million Stake in Repligen Co. (NASDAQ:RGEN)

Texas Permanent School Fund Corp boosted its holdings in Repligen Co. (NASDAQ:RGEN) by 1.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 45,443 shares of the biotechnology company’s stock after acquiring an additional 588 shares during the period. Texas Permanent School Fund Corp’s holdings in Repligen were worth $8,358,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. YHB Investment Advisors Inc. acquired a new position in shares of Repligen in the 1st quarter valued at approximately $26,000. Benjamin F. Edwards & Company Inc. raised its position in shares of Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 146 shares in the last quarter. Principal Securities Inc. acquired a new position in shares of Repligen in the 4th quarter valued at approximately $48,000. CWM LLC raised its position in shares of Repligen by 19.9% in the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 60 shares in the last quarter. Finally, Signaturefd LLC raised its position in shares of Repligen by 48.4% in the 4th quarter. Signaturefd LLC now owns 417 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 136 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Trading Up 4.3 %

RGEN traded up $5.22 during trading on Thursday, reaching $126.17. 633,978 shares of the company’s stock were exchanged, compared to its average volume of 596,097. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.05 billion, a PE ratio of 504.70, a price-to-earnings-growth ratio of 4.01 and a beta of 0.95. The firm has a fifty day moving average price of $143.88 and a two-hundred day moving average price of $170.32.

Repligen (NASDAQ:RGEN) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business had revenue of $151.31 million for the quarter, compared to the consensus estimate of $150.06 million. During the same period in the previous year, the firm earned $0.64 earnings per share. The company’s revenue was down 17.1% compared to the same quarter last year. As a group, equities research analysts forecast that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Martin D. Madaus acquired 1,615 shares of Repligen stock in a transaction dated Friday, June 14th. The shares were bought at an average cost of $124.94 per share, with a total value of $201,778.10. Following the purchase, the director now owns 4,613 shares in the company, valued at approximately $576,348.22. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the transaction, the chief executive officer now owns 163,177 shares in the company, valued at approximately $27,456,162.02. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on RGEN shares. Guggenheim started coverage on shares of Repligen in a research report on Tuesday, June 18th. They issued a “neutral” rating for the company. JPMorgan Chase & Co. lowered their price objective on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and lowered their price objective for the stock from $180.00 to $155.00 in a research report on Wednesday, June 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $193.00.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.